Last ¥1,127 JPY
Change Today -10.00 / -0.88%
Volume 423.2K
4571 On Other Exchanges
As of 2:00 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

nanocarrier co ltd (4571) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/30/13 - ¥2,636
52 Week Low
05/21/14 - ¥885.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOCARRIER CO LTD (4571)

Related News

No related news articles were found.

nanocarrier co ltd (4571) Related Businessweek News

No Related Businessweek News Found

nanocarrier co ltd (4571) Details

NanoCarrier Co., Ltd. researches and develops various pharmaceuticals for the treatment of cancer in Japan. The company’s products include Nanoplatin for the treatment of pancreatic, solid, and non small cell lung cancer; DACH-Platin Micelle for the treatment of bowel cancer; Epirubicin Micelle; and Paclitaxel Micelle for the treatment of stomach and breast cancer. It also develops Sensor Linked Micelle, small interfering RNA Micelle, and Protein Micelle, as well as Docetaxel Micelle for the treatment of breast, non-small cell lung, uterus, ovarian, and prostatic cancer. The company was founded in 1996 and is headquartered in Kashiwa, Japan.

40 Employees
Last Reported Date: 06/26/14
Founded in 1996

nanocarrier co ltd (4571) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nanocarrier co ltd (4571) Key Developments

NanoCarrier Co., Ltd. Presents at Bank of America Merrill Lynch Japan Conference 2014, Sep-08-2014

NanoCarrier Co., Ltd. Presents at Bank of America Merrill Lynch Japan Conference 2014, Sep-08-2014 . Venue: Grand Hyatt Tokyo, Tokyo, Japan.

NanoCarrier Co., Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2014; Reaffirms Earnings Guidance for the Full Year Ending March 31, 2015

NanoCarrier Co., Ltd. reported earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net sales of JPY 56 million compared to JPY 149 million a year ago. Operating loss was JPY 381 million compared to JPY 277 million a year ago. Ordinary loss was JPY 461 million compared to JPY 190 million a year ago. Net loss was JPY 461 million or JPY 11.47 per diluted share compared to JPY 191 million or JPY 5.86 per diluted share a year ago. Loss before income taxes was JPY 461.242 million compared to JPY 190.444 million a year ago. The company provided earnings guidance for the full year ending March 31, 2015. For the year, the company expects net sales of JPY 330 million, operating loss of JPY 1,955 million, ordinary loss of JPY 1,929 million and net loss of JPY 1,970 million or JPY 48.92 per share. Sales for the current fiscal year (ending March 31, 2015) are expected to be JPY 330 million (a decrease of 30.1% compared to the previous fiscal year), mainly comprised of the supply revenues of the trial drug materials and cosmetics materials under the existing contracts, and other contract revenues. Operating loss and the ordinary loss are expected to be JPY 1,955 million (compared with the loss of JPY 1,123 million for the previous fiscal year) and JPY 1,929 million (compared with the loss of JPY 1,094 million for the previous fiscal year), respectively. The net loss is expected to increase to JPY 1,970 million (from JPY 1,113 million for the previous fiscal year). Overall, the forecast of the financial performance for the full year remains unchanged from the projection presented in the 'Financial Results for Fiscal Year ended March 31, 2014 (non-consolidated)' reported on May 13, 2014.

NanoCarrier Co., Ltd. to Report Q1, 2015 Results on Aug 08, 2014

NanoCarrier Co., Ltd. announced that they will report Q1, 2015 results on Aug 08, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4571:JP ¥1,127.00 JPY -10.00

4571 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4571.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4571 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 112.2x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 84.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOCARRIER CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at